As we step into 2025, the future of health care in India looks both dynamic and promising. With technological advancements ...

India lacks a dedicated early warning system for detecting and responding to emerging drug threats like NPS or synthetic ...

Traditional defensive stocks Johnson & Johnson, United Health, and Procter & Gamble are all up and helping to keep the S&P ...

Elective surgeries in India are typically performed within one to four weeks, making medical care far more accessible. Cost of medical consultations Healthcare in the US is known for its high ...

Eli Lilly launches anti-obesity and diabetes drug Mounjaro in India, priced competitively at Rs 14,000-17,500, a fraction of ...

With increasing regulatory scrutiny and the introduction of stricter laws, cartelised industries in India face a higher risk of exposure and penalties. The health and pharma sector, which has ...

The e-commerce sector stands out as an exception, maintaining its competitive pay. Following e-commerce, there are other sectors, including automotive, pharmaceuticals, manufacturing, and financial ...

A key drug in this class, semaglutide is set to go off-patent in March next year, and several Indian players, including Mankind Pharma ... a major public health challenge in India.

Piramal Critical Care and BrePco Biopharma received UK approval for Neoatricon, a paediatric Dopamine Hydrochloride solution.